SOME CONTEMPORARY ETHICAL CONSIDERATIONS RELATED TO ORGAN-TRANSPLANTATION

被引：9

作者：

COHEN, B

DAMARO, J

机构：

[1] Eurotransplant Foundation, Leiden, NL-2301 CH

[2] Department of Immunohematology and Blood Bank, University Hospital, Leiden, NL-2300 RC

来源：

TRANSPLANT INTERNATIONAL | 1995年 / 8卷 / 03期

关键词：

ALLOCATION; ORGANS FOR TRANSPLANTATION; TRANSPLANTATION; ETHICS; SHORTAGE ORGAN;

D O I：

10.1007/BF00336545

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

With the increasing number of transplantable organs and tissues, as well as improvements in transplantation results. has come a severe shortage of organ donors, Consequently, new ethical dilemmas related to the fair allocation of available organs and the use of alternative sources of donor organs, are of growing concern. Establishing fair allocation priorities is a serious problem in organ transplantation. Ethically, they should be defined by society as a whole rather than exclusively by the medical profession. Proposed solutions for the organ donor shortage, each with their unique ethical constraints. include the use of related donors, partial organ transplantation, cell transplantation using fetal tissue, and the use of animal organs (''senotransplantation''). Commercial trading in donor organs must be regarded as an unethical activity rather than an ethical dilemma since the donors are motivated by monetary rather than by humanitarian reasons. These ethical dilemmas could be largely avoided by an effective reduction in the severe shortage of postmortal organ donations.

引用

页码：238 / 243

页数：6

共 22 条

[1]

de Boer J., Cohen B., Zantvoort F.A., D'Amaro J., Thorogood J., Persijn G.G., Results of acute heart retransplantation in Eurotransplant, Lancet, 337, (1991)

[2]

Deltz E., Medical risk and benefit in living small-bowel segment donors, Organ replacement therapy: ethics justice, commerce, Part II, pp. 110-116, (1990)

[3]

Hammer C., Xenografting: its future role in clinical organ transplantation. Organ replacement therapy: ethics, justice, commerce, Part VI, pp. 512-518, (1990)

[4]

Kootstra G., Ruers T.J.M., Vroemen J.P.A.M., The non-heartheating donor: contributing to the organ shortage, Transplant Proc, 20, (1986)

[5]

Kupsch A., Sauer H., Oertel W.H., Transplantation of fetal dopamine-synthesizing cells: experiment or therapy of Parkinson's disease?, Organ replacement therapy: ethics, justice, commerce, Part VI, pp. 467-483, (1990)

[6]

Land W., Accepted resolutions. Resolution 8, Organ replacement therapy: ethics, justice, commerce, Part VII, (1990)

[7]

Landgraf R., Fetal islet cell transplantation: state of the art, Organ replacement therapy: ethics, justice, commerce, Part VI, pp. 484-490, (1990)

[8]

Landgraf R., Medical risk and benefit in living pancreas segment donors, Organ replacement therapy: ethics, justice, commerce, Part II, pp. 106-109, (1990)

[9]

Laskow D.A., Diethelm A.G., Hudson S.L., Deierhoi M.H., Barber W.H., Barger B.O., Gaston R.S., Julian B.A., Curtis J.J., Analysis of 22 years experience in living-related transplantation at the University of Alabama in Birmingham, Clinical transplants, pp. 179-191, (1991)

[10]

Margreiter R., Medical risk and benefit in living pancreas segment donors, Organ replacement therapy: ethics, justice, commerce, Part II, pp. 102-105, (1990)

← 1 2 3 →